AT-Patch (ATP-C130/ATP-C70) vs Bunkerhill ECG-EF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AT-Patch (ATP-C130/ATP-C70)

by ATsens Co.

Bunkerhill ECG-EF

by Bunkerhill Health

AI Verdict

AT-Patch is a wearable device designed for continuous, long-term ECG monitoring and arrhythmia detection, providing extended data collection. In contrast, Bunkerhill ECG-EF is a software-only AI algorithm that analyzes routine 12-lead ECGs to detect reduced left ventricular ejection fraction, primarily aiding in early heart failure risk identification. While both leverage AI for cardiac assessment, they address distinct clinical needs and utilize different types of ECG data.

Choose AT-Patch (ATP-C130/ATP-C70) if…

Choose AT-Patch if you require extended, continuous cardiac monitoring to capture intermittent arrhythmias or symptoms that may not manifest during a brief clinical encounter. This wearable device is ideal for patients needing up to 14 days of comfortable, shower-proof ECG recording with integrated AI analysis for comprehensive arrhythmia detection in an ambulatory setting.

View AT-Patch (ATP-C130/ATP-C70) →

Choose Bunkerhill ECG-EF if…

Choose Bunkerhill ECG-EF if your primary objective is to rapidly screen a broad patient population for reduced left ventricular ejection fraction (LVEF ≤ 40%) using existing, routine 12-lead electrocardiograms. This AI algorithm seamlessly integrates with EHRs to aid in the early identification of patients at risk for heart failure, optimizing automated clinical workflows without requiring additional patient-specific devices.

View Bunkerhill ECG-EF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AT-Patch (ATP-C130/ATP-C70)	Bunkerhill ECG-EF
Pricing	N/a	Contact sales for pricing details.
Deployment	Wearable device for patients; analysis software deployed on-premise at medical institutions.	Cloud-native platform (Carebricks) that integrates with existing health system infrastructure like EHRs.
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AT-Patch (ATP-C130/ATP-C70)

Tool A (AT-Patch) offers superior patient usability with its compact, lightweight, shower-proof design, and the convenience of no charging or electrode replacement for up to 14 days. The accompanying smartphone app for live ECG viewing further enhances the patient's direct interaction and comfort during monitoring. While Tool B focuses on clinician integration, Tool A's direct patient-facing design provides a more comprehensive usability experience.

Clinical Value

AT-Patch (ATP-C130/ATP-C70)

Tool A (AT-Patch) provides up to 14 days of continuous ECG monitoring with AI-powered analysis for enhanced arrhythmia detection, offering a broader and more comprehensive diagnostic window for various cardiac rhythm disorders. While Tool B offers valuable early identification of reduced LVEF from routine ECGs, Tool A's extended, high-accuracy monitoring for transient events provides a more extensive diagnostic clinical utility.

Pricing & Value

Tie

Neither Tool A nor Tool B provides publicly available pricing information, both requiring direct contact for details. Without any specific cost data or transparent pricing models, it is impossible to compare their relative value or determine which offers a better financial proposition.

Enterprise Readiness

Bunkerhill ECG-EF

Tool B (Bunkerhill ECG-EF) explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical requirements for enterprise adoption in healthcare. Its seamless integration with EHRs and clinical archives further enhances its readiness for large-scale deployment compared to Tool A, which only 'likely' meets HIPAA and doesn't explicitly mention a BAA.

Innovation

Bunkerhill ECG-EF

Tool B (Bunkerhill ECG-EF) demonstrates significant innovation by leveraging AI to extract a critical, previously non-obvious biomarker (reduced LVEF) from routine 12-lead ECGs, transforming a standard diagnostic into a powerful screening tool for heart failure. This ability to derive new, actionable insights from existing, widely available data represents a more transformative application of AI in clinical practice.

Support & Docs

Tie

Neither the provided structured facts nor general web searches offer sufficient specific details regarding the quality, availability, or scope of support services and documentation for either tool. Both appear to offer standard contact-based support, making a definitive comparison impossible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AT-Patch (ATP-C130/ATP-C70)	Bunkerhill ECG-EF
Product Name	AT-Patch (ATP-C130/ATP-C70)	Bunkerhill ECG-EF
Company	ATsens Co.	BunkerHill Health
Description/Type	FDA-cleared wearable ECG monitor offering up to 14 days of continuous cardiac monitoring with high accuracy, a shower-proof design, and integrated AI-powered analysis software for enhanced arrhythmia detection.	FDA-cleared artificial intelligence algorithm that detects reduced left ventricular ejection fraction (LVEF u2264 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure.
Primary AI Function	AI/machine learning algorithms for ECG analysis (enhanced arrhythmia detection)	AI algorithm to detect reduced Left Ventricular Ejection Fraction (LVEF u2264 40%)
Data Input	Up to 14 days of continuous ECG monitoring	Routine 12-lead ECG data

Videos

Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and Bunkerhill ECG-EF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and diagnostic goals of AT-Patch versus Bunkerhill ECG-EF?

AT-Patch focuses on continuous cardiac monitoring for arrhythmia detection over an extended period, offering up to 14 days of monitoring. Bunkerhill ECG-EF uses an AI algorithm to detect reduced left ventricular ejection fraction (LVEF u2264 40%) from routine 12-lead ECGs, aiding in the early identification of patients at risk for heart failure.

How do these tools integrate into existing clinical workflows and IT infrastructure?

AT-Patch involves a wearable device for patients, with its analysis software deployed on-premise at medical institutions. Bunkerhill ECG-EF is a software-only solution designed to integrate seamlessly with Electronic Medical Records (EMR) or ECG Management Systems (EMS).

What type of ECG data is utilized by each tool?

AT-Patch acquires continuous ECG data for up to 14 days via its proprietary wearable sensor. Bunkerhill ECG-EF analyzes routine 12-lead electrocardiogram data, which is typically already available in clinical archives.

Does either tool require new hardware investment for implementation?

Yes, AT-Patch requires the use of its proprietary wearable ECG monitor for data acquisition. In contrast, Bunkerhill ECG-EF is a software-only medical device that integrates with existing EHRs and ECG systems, requiring no new hardware investment.

What specific AI capabilities do these tools offer to aid in diagnosis?

AT-Patch utilizes AI/machine learning algorithms within its AT-Report software for enhanced ECG analysis and arrhythmia detection. Bunkerhill ECG-EF employs an AI algorithm specifically designed to detect reduced Left Ventricular Ejection Fraction (LVEF u2264 40%) from 12-lead ECGs.

What is the patient's role and experience with each device?

With AT-Patch, patients wear a compact, shower-proof device for continuous monitoring and can use a smartphone app for live ECG viewing and symptom recording. Bunkerhill ECG-EF is a software-only tool that analyzes existing ECG data, requiring no direct patient interaction beyond the standard ECG procedure.